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Investigating UK Biobank blood  
metrics variation to inform cell therapy 
manufacturing process control 
 
Analysis Methodology 
 
UK Biobank [4] was petitioned for access to 502,664 patient records (Table 1). Access to blood metrics and associated data tags were obtained, with emphasis on; age, health state, gender, weight, centre 
location. These a were prioritised to align with existing analyses completed on multi site and single site clinical centre data [1, 2, 3]. 
 
At the point that this investigation was carried out, UK Biobank did not directly measure cell markers that specifically identified stem cells such as HSCs. CD34+ cell counts would have been appropriate to 
directly compare the relatively healthy population of the UK Biobank to the relatively unwell populations in multi and single centre clinical analysis [1, 2, 3]. UK Biobank does however record red blood cell 
counts, WBC counts and the specific subsets of WBCs such as leukocytes and monocytes. Biological variation was therefore explored as a function of WBCs rather than and as a surrogate to HSCs.  
Research Aims 
To investigate whether UK Biobank blood metric data shows variation in White Blood Cell count that can act as a healthy population benchmark for Stem Cell Therapy manufacturing process control   
Conclusions 
 
•  White Blood Cell (WBC) count can vary up to 4 orders of magnitude (7.00 x 107 cells/litre and 3.90 x 1011 cells/litre) 
•  Gender appears to impact the amount of variation in WBC and TNC counts 
•  Increasing age shows a trend towards increasing variation in WBC and TNC counts 
•  Increasing weight shows a trend towards decreasing variation in WBC and TNC counts 
•  UK Assessment Centre, analogous of geographical area, appears to have a statistically significant effect on WBC counts 
•  Significant outliers exists in the data that represent a state of health, keyed uniquely to be the individual, and cannot be removed to smoothen a statistical distribution.  
Cell therapies are becoming increasingly viable on a clinical basis, to the extent where upscale to centralised or distributed manufacture is possible. Manufacturing processes and control paradigms have been 
traditionally predicated on minimal variation of the product and the capability to control the manufacturing process using product limits. Automation within traditional manufacture that has adhered to this philosophy 
has led to in-process, statistical process control. Whilst there is a requirement to translate and scale up the production of cell therapies, the manufacturing processes need to understand and accommodate the 
issues associated with, and context of, using cells as products.  
 
Conventional manufacturing process control would normally be defined as typically 10% to 30% of the defined process limits i.e. less than 0.1 orders of  magnitude. Existing work has already defined significant 
variation of starting materials in Haematopoetic Stem Cell (HSC) therapy exemplars [1, 2, 3] that may be 3 to 6 orders of magnitude variation. But there is now a need to examine a baseline healthy population for 
variation in blood metrics to further inform potential manufacturing process control paradigms. 
 
 
Key Results 
 
An important assumption that has been made is that the UK Biobank (500,000+ records) is a representative sample of the UK general population. The original data gathering studies were carried out on a 
volunteer-basis that may have influenced the population – people of a mindset that were more inclined to volunteer, and may reflect a particularly health state, lifestyle or character. 
 
The variation in WBC count can be between 7.00 x 107 cells/litre and 3.90 x 1011 cells/litre – a variation of up to four orders of magnitude. Both the TNC count and WBC counts within the UK Biobank had 
similar ranges (range; 3.90 x 1011  and 3.86 x 1011 cells / litre), similar distributions around the mean (standard deviation; 2.12 x 109 cells / litre and 2.10 x 109 cells / litre), and similar data spread (variance; 
4.51 x 1018 cells / litre and 4.42 x 1018 cells / litre). This analysis aligns with the lower end of variation seen in the multi site and single site clinical centre analysis [1, 2, 3]. 
 
The population characteristics examined in this research (age (Figure 1), disease state, gender, weight (Figure 2) and, geographical location (Figure 3)) all appear to influence the biological variation 
encountered but there is an implication this relates to a multiplicative effect based on multiple, interacting variables, rather than the result of a handful of key metrics. However, there are several potentially 
influential metrics that were not examined which may play a key role e.g. alcohol consumption, diet, concurrent medication and smoking. 
 
A notable observation from this analysis is the considerable number of data ‘outliers’. These outliers represent a state of health, keyed uniquely to be the individual, and cannot be removed to smoothen a 
statistical distribution. Understanding these outliers, and what they represent, is critical to understanding the behaviour of the starting material and the process; it will influence the way in which cellular 
therapies are manufactured and monitored, and act as a guide as to whether biological variation should be accommodated or should be controlled. 
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Figure 1: The spread of WBC count per litre measured per 
individual participant, against age in years  
Figure 2: Calculated WBC count / litre per individual as a 
function of weight in kilograms 
Figure 3: WBC count / litre per individual as a function of 
location of UK Assessment Centre 
 
The comma-separated variation output was processed in IBM’s SPSS 22.0 statistics package. 
Distributions of cell metrics were analysed for normality. The minimum, maximum and range data were 
defined along with Standard Deviation and Variance. 
 
These biological measurements were found to be non-parametric and consequently non-parametric 
statistical tools were used to compare median and distribution of the data. The Pearson product-moment 
correlation co-efficient was used to measure linear correlation. Independent samples median tests, 
independent Mann-Whitney tests (for two independent groups, such as gender) and independent sample 
Kruskal-Wallis (for multiple independent groups) tests were used to measure whether the median or the 
distribution of population differs significantly between groups. Example results for variation as a function of 
age, weight, and UK Assessment Centre location are shown in Figures 1, 2 and 3 respectively. 
Table 1: Summary of Participants within UK Biobank [4] 
